Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

3.15

Today's Change

-0.41 (11.51%)

Day's Change

2.65 - 3.55

Trading Volume

6,957,418

Overview

Market Cap

1 Billion

Shares Outstanding

321 Million

Avg Volume

1,778,344

Avg Price (50 Days)

3.78

Avg Price (200 Days)

5.67

PE Ratio

-21.00

EPS

-0.15

Earnings Announcement

20-Aug-2025

Previous Close

3.56

Open

3.55

Day's Range

2.65 - 3.55

Year Range

2.5 - 8.975

Trading Volume

6,957,418

Price Change Highlight

1 Day Change

5 Day Change

1 Month Change

3 Month Change

6 Month Change

Ytd Change

1 Year Change

3 Year Change

5 Year Change

10 Year Change

Max Change

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment